Patents by Inventor Aiden Y. PARK

Aiden Y. PARK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CHIMERIC GENOME ENGINEERING MOLECULES AND METHODS
    Publication number: 20220389404
    Abstract: The present disclosure provides compositions and methods for increasing mutation efficiency and homologous recombination rates of site-specific endonucleases. The compositions and methods comprise a chimeric polypeptide comprising a site-specific endonuclease or a domain thereof and a functional moiety. The current inventions relate to functional enhancement of the CRISPR-Cas enzymes. Disclosed herein include possible variants and their intended improvements.
    Type: Application
    Filed: March 1, 2022
    Publication date: December 8, 2022
    Inventors: Jongjin PARK, Ji Young YOON, Sunmee CHOI, Mijin PARK, Slki PARK, Aiden Y. PARK, Jung Hyuk LEE, Junghak LIM, Dong Wook KIM, Sunghwa CHOE
  • Sequence-specific in vivo cell targeting
    Patent number: 11491208
    Abstract: Enhanced, specific nucleic acid targeting complexes comprising endo and exonuclease activity, and related methods that allow both targeted degradation of specific and/or non-specific nucleic acids in vivo and specific temporal regulation of nuclease activity to prevent off-target activity are disclosed herein. Through practice of the disclosure, nucleic acids, and cells harboring them, such as cancer cells or pathogens, are selectively degraded in vivo.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: November 8, 2022
    Assignees: GFLAS LIFE SCIENCES, INC., SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Sungyong In, Sunghwa Choe, Mi Jin Park, Aiden Y. Park, Jung Hak Lim, Dong Wook Kim, Youngdong Yoo, Jongjin Park
  • SEQUENCE-SPECIFIC IN VIVO CELL TARGETING
    Publication number: 20220313796
    Abstract: Enhanced, specific nucleic acid targeting complexes comprising endo and exonuclease activity, and related methods that allow both targeted degradation of specific and/or non-specific nucleic acids in vivo and specific temporal regulation of nuclease activity to prevent off-target activity are disclosed herein. Through practice of the disclosure, nucleic acids, and cells harboring them, such as cancer cells or pathogens, are selectively degraded in vivo.
    Type: Application
    Filed: May 11, 2022
    Publication date: October 6, 2022
    Inventors: Sungyong IN, Sunghwa CHOE, Mi Jin PARK, Aiden Y. PARK, Jung Hak LIM, Dong Wook KIM, Youngdong YOO, Jongjin PARK
  • Chimeric genome engineering molecules and methods
    Patent number: 11293019
    Abstract: The present disclosure provides compositions and methods for increasing mutation efficiency and homologous recombination rates of site-specific endonucleases. The compositions and methods comprise a chimeric polypeptide comprising a site-specific endonuclease or a domain thereof and a functional moiety. The current inventions relate to functional enhancement of the CRISPR-Cas enzymes. Disclosed herein include possible variants and their intended improvements.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: April 5, 2022
    Assignees: GFLAS LIFE SCIENCES, INC., SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Jongjin Park, Ji Young Yoon, Sunmee Choi, Mijin Park, Slki Park, Aiden Y. Park, Jung Hyuk Lee, Junghak Lim, Dong Wook Kim, Sunghwa Choe
  • SEQUENCE-SPECIFIC IN VIVO CELL TARGETING
    Publication number: 20210077594
    Abstract: Enhanced, specific nucleic acid targeting complexes comprising endo and exonuclease activity, and related methods that allow both targeted degradation of specific and/or non-specific nucleic acids in vivo and specific temporal regulation of nuclease activity to prevent off-target activity are disclosed herein. Through practice of the disclosure, nucleic acids, and cells harboring them, such as cancer cells or pathogens, are selectively degraded in vivo.
    Type: Application
    Filed: September 25, 2020
    Publication date: March 18, 2021
    Inventors: Sungyong IN, Sunghwa CHOE, Mi Jin PARK, Aiden Y. PARK, Jung Hak LIM, Dong Wook KIM, Youngdong YOO, Jongjin PARK
  • CHIMERIC GENOME ENGINEERING MOLECULES AND METHODS
    Publication number: 20210054362
    Abstract: The present disclosure provides compositions and methods for increasing mutation efficiency and homologous recombination rates of site-specific endonucleases. The compositions and methods comprise a chimeric polypeptide comprising a site-specific endonuclease or a domain thereof and a functional moiety. The current inventions relate to functional enhancement of the CRISPR-Cas enzymes. Disclosed herein include possible variants and their intended improvements.
    Type: Application
    Filed: December 21, 2018
    Publication date: February 25, 2021
    Inventors: Jongjin PARK, Ji Young YOON, Sunmee CHOI, Mijin PARK, Slki PARK, Aiden Y. PARK, Jung Hyuk LEE, Junghak LIM, Dong Wook KIM, Sunghwa CHOE